articleTop 1% cited
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Journal of the American Academy of Dermatology · 2007 · Vol. 58(1) · pp. 106–115
Alan Menter✉(The University of Texas Southwestern Medical Center)Stephen K. Tyring(The University of Texas Health Science Center at Houston)Kenneth B. Gordon(Loyola University Medical Center)Alexa B. Kimball(Harvard University)Craig L. Leonardi(Saint Louis University)Richard G. Langley(Dalhousie University)Bruce Strober(New York University)Martin Kaul(Abbott (Germany))Yihua Gu(Abbott Fund)Martin M. Okun(Abbott Fund)Kim Papp(Probity Medical Research)
Psoriasis: Treatment and PathogenesisDermatology and Skin DiseasesAutoimmune and Inflammatory Disorders ResearchMedicineAdalimumabPsoriasisRandomized controlled trialDermatologyPhysical therapyInternal medicineTumor necrosis factor alpha
MeSH terms
AdalimumabAdultAntibodies, MonoclonalDouble-Blind MethodFemaleHumansMaleMiddle AgedPsoriasisSeverity of Illness IndexTime FactorsTumor Necrosis Factor-alphaTreatment OutcomeAntibodies, Monoclonal, Humanized
Citations
872
FWCI
14.19
field-weighted impact
References
17
Percentile
99%
vs. same field & year
Citations per year
Cited by
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
British Journal of Dermatology · 2009 · 433 citations
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Journal of the American Academy of Dermatology · 2017 · 841 citations
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Journal of the American Academy of Dermatology · 2019 · 880 citations
Guidelines of care for the management of psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology · 2008 · 765 citations
Guidelines of care for the management of psoriasis and psoriatic arthritis
Journal of the American Academy of Dermatology · 2008 · 1,202 citations
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Journal of the American Academy of Dermatology · 2017 · 718 citations
Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies
Journal of the American Academy of Dermatology · 2018 · 631 citations
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Journal of the American Academy of Dermatology · 2015 · 538 citations
References
The effect of severe psoriasis on the quality of life of 369 patients
British Journal of Dermatology · 2006 · 557 citations
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
Arthritis & Rheumatism · 2004 · 1,168 citations
Psoriasis causes as much disability as other major medical diseases
Journal of the American Academy of Dermatology · 1999 · 1,493 citations
A Randomized Trial of Etanercept as Monotherapy for Psoriasis
Archives of Dermatology · 2003 · 469 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.